dr. osborne discusses targeting the her2 pathway in breast cancer
Published 7 years ago • 125 plays • Length 2:20Download video MP4
Download video MP3
Similar videos
-
1:07
dr. osborne on evaluating her2-positivity in breast cancer
-
2:10
dr. osborne on the benefits of dual-targeted therapy for her2 breast cancer
-
0:50
dr. osborne on pertuzumab in her2 breast cancer
-
1:10
dr. tripathy on targeting her2 in breast cancer
-
7:44
hormonal and her2-targeted therapy in early breast cancer
-
7:41
her2-targeted therapy in early stage her2 breast cancer
-
31:35
c. kent osborne, m.d., on advances in therapy for her2 breast cancer
-
1:20
dr. barrio on treatment options for her2 breast cancer
-
3:20
dr. hurvitz on eliminating anthracyclines in her2 breast cancer treatment
-
1:37
dr. hurvitz on how to navigate her2-targeted therapy in breast cancer
-
0:50
dr. ellis on immunotherapy in her2 breast cancer
-
3:45
evolving landscape of her2-targeted therapy in breast cancer
-
1:13
dr. hamilton on the efficacy of trastuzumab deruxtecan in her2-low breast cancer
-
0:51
dr. tripathy discusses immunotherapy in her2 breast cancer
-
2:01
dr. hurvitz on her2-targeted therapies in breast cancer
-
6:01
treating low-risk her2-positive breast cancer
-
1:39
dr. tolaney on novel approaches in treating her2-positive breast cancer
-
0:41
dr. freedman discusses dual her2-targeted therapy in breast cancer
-
2:36
dr. blackwell discusses tucatinib in her2 breast cancer